Bioniche Life Science (BNHLF)

[BioSpecialist]

LAST CHANCE TO GET IN CHEAP !

BNC HITS NEW 2 YEAR-HIGH TODAY = MAJOR BREAKOUT COMING
http://www.barchart.com/chart.php?sym=BNC.TO&style=technical&p=DO&d=O&sd=&ed=&size=M&log=0&t=CANDLE&v=1&g=1&evnt=1&late=1&o1=&o2=&o3=&x=28&y=9&sh=100&indicators=SMA%28200%2C16711680%29&chartindicator_2_code=SMA&chartindicator_2_param_0=200&chartindicator_2_param_1=16711680&addindicator=&submitted=1&fpage=&txtDate=#jump



Market cap of 90 M$ is wayyyyyyy undervalued .

Urocidin (Bladder Cancer) Phase 3 results in September (VERY LOW RISK ) . Only 105 Patients in current Phase 3 .Check out the POSITIVE Phase2 results from 2008 involving 128 Patients (see post below) !!!!


TWST: Give us more detail on that pipeline. What is near term and what is a little longer term?


Mr. McRae: The primary technology is called Mycobacterial Cell Wall-DNA Complex, and it sounds like a mouthful but really we found a naturally occurring bacteria where the DNA of the bacteria had a very unusual property ' it can actually kill cancer cells. It kills cancer cells in the face of mutations that would normally stop chemotherapy or radiation therapy from being effective. [B]This DNA is quite unique in that the tumor cells, even when they try to mutate around it, are unable to induce resistance to this compound; and it's extremely safe. We have a 70% complete response rate in patients who failed other therapies, so our Phase II data, which is in the public domain, shows about 128 patients with an average complete response of about 70%. These are patients who at the end of the study were disease-free and had really no side effects worth noting due to the product.[/B] The patients were able to maintain treatment, whereas without the treatments they drop out because of side effects, so that is our primary technology. It has been shown effective in-vitro in the lab against many different types of cancer. In fact, we can't find a cancer cell it doesn't kill. But in our clinical plan, it is bladder cancer first and prostate cancer second. In prostate cancer, we have completed a Phase I study